Abstract: Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders.

Abstract: Described herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, such as cancer, metabolic and blood disorders. Compounds of Formula (I) have the following structure of Formula (I).

Abstract: Embodiments disclosed herein can facilitate delivery of a document from a source to a destination over a network where an initial delivery attempt has been unsuccessful. Actions to be taken are based upon input conditions which may include a time-variable set of input conditions such as identifying non-business days and/or hours at the destination. The document can be a fax, an email, or a voice mail. The actions may include resubmitting the document to the network for a next delivery attempt, cancelling the document, sending a request to the source or destination for additional delivery information, identifying the destination as a technical problem, or a combination thereof.